Clinical Scorecard: Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

At a Glance

Key Highlights

• Baseline ELS positively correlates with hemoglobin levels and can predict moderate to severe anemia post anti-tumor treatment in AGC patients.
• The CO breath test provides a rapid, non-invasive, bedside-compatible method to estimate ELS, consistent with classical chromium-51 labeling.
• Patients with ELS less than 70 days have significantly lower hemoglobin levels and higher risk of developing anemia after treatment.

Guideline-Based Recommendations

Diagnosis

• Use routine hemoglobin measurement to diagnose anemia in AGC patients.
• Consider baseline ELS measurement via CO breath test to predict risk of moderate to severe anemia before anti-tumor treatment.

Management

• Implement personalized anemia prevention and management strategies for patients identified with shortened ELS prior to treatment.
• Monitor hemoglobin levels within 7–21 days after anti-tumor therapy to detect anemia development early.

Monitoring & Follow-up

• Perform serial hemoglobin assessments pre-treatment and 7–21 days post-treatment.
• Monitor ELS as a predictive biomarker to guide clinical decisions regarding anemia risk.

Risks

• Anemia in AGC patients may reduce treatment tolerance, worsen prognosis, and decrease quality of life.
• Shortened ELS indicates increased red blood cell destruction, increasing risk for moderate to severe anemia.

Patient & Prescribing Data

56 advanced gastric cancer patients undergoing anti-tumor treatments

Baseline ELS measurement can identify patients at higher risk for anemia, enabling tailored supportive care to improve outcomes.

Clinical Best Practices

• Screen AGC patients for anemia risk using baseline ELS prior to initiating anti-tumor therapy.
• Use the non-invasive CO breath test for rapid ELS assessment to facilitate bedside decision-making.
• Closely monitor hemoglobin changes within 3 weeks post-treatment to detect anemia onset early.
• Integrate ELS data with clinical parameters to personalize anemia management and improve patient quality of life.

References

• Global cancer statistics and gastric cancer burden
• Levitt’s CO breath test for erythrocyte lifespan estimation
• Wei et al. and Deng et al. linking anemia to gastric cancer prognosis